Elena A. Ivanova
Research Subjects
Research Interests
Elena A. Ivanova has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
T. A. Voronina
V. V. Zakusov Research Institute of Pharmacology, Moscow, Russia
21 shared publications- A. I. Matyushkin
НИИ фармакологии имени В. В. Закусова
14 shared publications - Anastasia G. Vasilchuk
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
13 shared publications - Tatiana A. Voronina
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
13 shared publications Татьяна Александровна Воронина
12 shared publicationsI. G. Kapitsa
V. V. Zakusov State Institute of Pharmacology, Moscow, Russia
10 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 37-44
Study of the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice bearing ACATOL colon adenocarcinoma in comparison with doxorubicin
Introduction. Matrix metalloproteinases (MMPs) belong to the family of zinc-dependent endopeptidases capable of degrading the main components of extracellular matrix proteins that form the basis of connective tissue; they are also involved in many pathological processes in the body. MMP-2 is actively expressed in lung cancer tissues, while MMP-2 and MMP-9 play a significant role in the development of colorectal cancer. Objective. To evaluate the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2 carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice using the AKATOL colon adenocarcinoma model. Materials and methods. AKATOL colon adenocarcinoma was implanted subcutaneously into the axillary region of male BALB/c mice at a dose of 1×10⁶ cells. From day 2 to day 15 of tumor development, GGM-27 was administered intraperitoneally (i.p.) at doses of 1 mg/kg and 10 mg/kg. Doxorubicin was used as a reference drug, administered at a dose of 5 mg/kg i.p. on days 2 and 4 of tumor development. The antitumor activity of GGM-27 was assessed by tumor growth inhibition (TGI) and lifespan extension (LSE). Results. After a 14-day course of i.p. administration of GGM-27 at a dose of 1 mg/kg, TGI was 72.8 % on day 21 of the experiment and 71 % on day 28. After i.p. administration of GGM-27 at a dose of 10 mg/kg, TGI was 63 % on day 21 and 56% on day 28. LSE after a course of GGM-27 at a dose of 10 mg/kg was 24 %. After two i.p. administrations of doxorubicin at a dose of 5 mg/kg, TGI was 82 % on day 21 and 69 % on day 28; however, two of the 12 animals died due to drug toxicity. Conclusions. Administration of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid at a dose of 1 mg/kg caused TGI. On day 21 of the experiment, with GGM-27 administration, TGI was 73 %, and on day 28, TGI was 71 %.
- 22 July 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 37-44
Open AccessStudy of the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice bearing ACATOL colon adenocarcinoma in comparison with doxorubicin
Introduction. Matrix metalloproteinases (MMPs) belong to the family of zinc-dependent endopeptidases capable of degrading the main components of extracellular matrix proteins that form the basis of connective tissue; they are also involved in many pathological processes in the body. MMP-2 is actively expressed in lung cancer tissues, while MMP-2 and MMP-9 play a significant role in the development of colorectal cancer. Objective. To evaluate the effect of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2 carboxylic acid (GGM-27) on tumor growth and survival in BALB/c mice using the AKATOL colon adenocarcinoma model. Materials and methods. AKATOL colon adenocarcinoma was implanted subcutaneously into the axillary region of male BALB/c mice at a dose of 1×10⁶ cells. From day 2 to day 15 of tumor development, GGM-27 was administered intraperitoneally (i.p.) at doses of 1 mg/kg and 10 mg/kg. Doxorubicin was used as a reference drug, administered at a dose of 5 mg/kg i.p. on days 2 and 4 of tumor development. The antitumor activity of GGM-27 was assessed by tumor growth inhibition (TGI) and lifespan extension (LSE). Results. After a 14-day course of i.p. administration of GGM-27 at a dose of 1 mg/kg, TGI was 72.8 % on day 21 of the experiment and 71 % on day 28. After i.p. administration of GGM-27 at a dose of 10 mg/kg, TGI was 63 % on day 21 and 56% on day 28. LSE after a course of GGM-27 at a dose of 10 mg/kg was 24 %. After two i.p. administrations of doxorubicin at a dose of 5 mg/kg, TGI was 82 % on day 21 and 69 % on day 28; however, two of the 12 animals died due to drug toxicity. Conclusions. Administration of 1-({4-[(2,4-dichlorobenzoyl)amino]phenyl}sulfonyl-(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid at a dose of 1 mg/kg caused TGI. On day 21 of the experiment, with GGM-27 administration, TGI was 73 %, and on day 28, TGI was 71 %.
- Open Access
- 15 July 2026
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 25 (2) , 81-88
Efficacy of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine in monotherapy and in combination with doxorubicin on AKATOL colon cancer in mice
Background. Compounds capable of suppressing inflammation and modulating the antitumor immune response may enhance the effectiveness of cytostatic therapy. In this regard, the strategy of combined use of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine with classical chemotherapy drugs is of particular interest. Aim. Evaluation of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine (base SNK-411 and salt SNK-578) per se or with doxorubicin on tumor growth inhibition and survival in the murine AKATOL colon adenocarcinoma model. Materials and methods. Antitumor activity of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine was studied in tests on BALB / c mice using the AKATOL colon adenocarcinoma model. A standard graft of 1 × 106 AKATOL tumor cells was administered to each mouse. Starting on day 2, mice received treatment with SNK-578 (10 mg / kg, intraperitoneal) or SNK-411 per os (25 mg / kg) or their combinations with doxorubicin daily. A positive control group received doxorubicin (5 mg / kg, intraperitoneal) on days 2 and 4. The endpoints for assessing antitumor activity were the percentage of tumor growth inhibition (TGI) and increase in lifespan. Results. Monotherapy with SNK-411 and SNK-578 showed high efficacy (TGI ~74 % on day 21). Doxorubicin showed similar efficacy (inhibition of tumor growth 82 %), however, in this group, the death of 2 out of 12 animals was recorded. The combination therapy surpassed the monotherapy with doxorubicin in terms of tumor growth suppression and did not cause the death of animals. The increase in lifespan in the SNK-411 and SNK-578 groups was 31 and 33 %, respectively. Conclusion. Base SNK-411 and salt SNK-578 show antitumor activity and synergize with doxorubicin, reducing its toxicity. These results corroborate earlier data from cervical cancer RSHM-5 and Lewis lung carcinoma models.
- 15 July 2026
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 25 (2) , 81-88
Open AccessEfficacy of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine in monotherapy and in combination with doxorubicin on AKATOL colon cancer in mice
Background. Compounds capable of suppressing inflammation and modulating the antitumor immune response may enhance the effectiveness of cytostatic therapy. In this regard, the strategy of combined use of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine with classical chemotherapy drugs is of particular interest. Aim. Evaluation of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine (base SNK-411 and salt SNK-578) per se or with doxorubicin on tumor growth inhibition and survival in the murine AKATOL colon adenocarcinoma model. Materials and methods. Antitumor activity of 2-isobutyl-4,6-dimethyl-5-oxypyrimidine was studied in tests on BALB / c mice using the AKATOL colon adenocarcinoma model. A standard graft of 1 × 106 AKATOL tumor cells was administered to each mouse. Starting on day 2, mice received treatment with SNK-578 (10 mg / kg, intraperitoneal) or SNK-411 per os (25 mg / kg) or their combinations with doxorubicin daily. A positive control group received doxorubicin (5 mg / kg, intraperitoneal) on days 2 and 4. The endpoints for assessing antitumor activity were the percentage of tumor growth inhibition (TGI) and increase in lifespan. Results. Monotherapy with SNK-411 and SNK-578 showed high efficacy (TGI ~74 % on day 21). Doxorubicin showed similar efficacy (inhibition of tumor growth 82 %), however, in this group, the death of 2 out of 12 animals was recorded. The combination therapy surpassed the monotherapy with doxorubicin in terms of tumor growth suppression and did not cause the death of animals. The increase in lifespan in the SNK-411 and SNK-578 groups was 31 and 33 %, respectively. Conclusion. Base SNK-411 and salt SNK-578 show antitumor activity and synergize with doxorubicin, reducing its toxicity. These results corroborate earlier data from cervical cancer RSHM-5 and Lewis lung carcinoma models.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Effect of cyclooxygenase inhibitors, ethylmethylhydroxypyridine succinate and their combinations in a collagen-induced arthritis model in BALB/c mice
Background . Inflammation intensifies lipid peroxidation and damages cell membranes. Therefore, the use of antioxidant and membrane-protective agents in combination with widely prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance the effect of the therapy. Ethylmethylhydroxypyridine succinate (EMHPS), which has antioxidant and membrane-stabilizing properties, enhances the antiexudative effect of diclofenac sodium and etoricoxib after a single oral administration in rats and mice. Objective . Evaluation of the effect of EMGPS, diclofenac sodium, etoricoxib and combinations of these NSAIDs with EMGPS with a course of oral administration in a collagen-induced arthritis model (CIA) in BALB/c mice. Methods . CIA was modeled by double injection of bovine collagen type II (BC) emulsified with complete Freund's adjuvant into the base of the tail of BALB/c mice, 21 days apart. Arthritis severity, paw edema, hyperalgesia, and motor deficits were recorded. On day 21 after the 2nd BC injection, serum was obtained for evaluation of the concentration of the collagen degradation marker oxyproline and the activity of the antioxidant enzymes catalase and glutathione peroxidase. NSAIDs at a dose of 1 mg/kg, EMHPS at a dose of 25 mg/kg, and combinations of EMHPS with NSAIDs were administered orally daily, starting on day of the 2nd BC injection for 21 days. Results . Mice with CIA developed swelling of the paws, the maximum of an exudative inflammation was observed on days 4–17 after the 2nd injection of BC, then joint deformation was more pronounced, and the concentration of oxyproline in the serum increased. Diclofenac sodium had an antiexudative effect on the 7th day of its administration. Etoricoxib delayed the manifestation of symptoms of arthritis in animals, had an antiexudative effect on the 7th day of its administration, but increased the concentration of oxyproline in serum. EMHPS delayed the manifestation of symptoms of arthritis and reduced the concentration of oxyproline in serum. EMHPS when administered together with diclofenac sodium or etoricoxib had a corrective effect on the severity of symptoms of arthritis and reduced swelling on the 7th day of its administration. EMHPS when administered together with diclofenac sodium or etoricoxib but not NSAIDs and EMHPS per se reduced hyperalgesia on the 7th day of its administration. EMHPS when administered together with diclofenac sodium reduced the level of oxyproline, and when administered with etoricoxib, it prevented the increase in oxyproline level in the serum caused by etoricoxib. Conclusion . The combined use of EMHPS with diclofenac sodium and etoricoxib increases the effect of these NSAIDs in the collagen-induced arthritis model in BALB/c mice.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Effect of cyclooxygenase inhibitors, ethylmethylhydroxypyridine succinate and their combinations in a collagen-induced arthritis model in BALB/c mice
Background . Inflammation intensifies lipid peroxidation and damages cell membranes. Therefore, the use of antioxidant and membrane-protective agents in combination with widely prescribed nonsteroidal anti-inflammatory drugs (NSAIDs) can enhance the effect of the therapy. Ethylmethylhydroxypyridine succinate (EMHPS), which has antioxidant and membrane-stabilizing properties, enhances the antiexudative effect of diclofenac sodium and etoricoxib after a single oral administration in rats and mice. Objective . Evaluation of the effect of EMGPS, diclofenac sodium, etoricoxib and combinations of these NSAIDs with EMGPS with a course of oral administration in a collagen-induced arthritis model (CIA) in BALB/c mice. Methods . CIA was modeled by double injection of bovine collagen type II (BC) emulsified with complete Freund's adjuvant into the base of the tail of BALB/c mice, 21 days apart. Arthritis severity, paw edema, hyperalgesia, and motor deficits were recorded. On day 21 after the 2nd BC injection, serum was obtained for evaluation of the concentration of the collagen degradation marker oxyproline and the activity of the antioxidant enzymes catalase and glutathione peroxidase. NSAIDs at a dose of 1 mg/kg, EMHPS at a dose of 25 mg/kg, and combinations of EMHPS with NSAIDs were administered orally daily, starting on day of the 2nd BC injection for 21 days. Results . Mice with CIA developed swelling of the paws, the maximum of an exudative inflammation was observed on days 4–17 after the 2nd injection of BC, then joint deformation was more pronounced, and the concentration of oxyproline in the serum increased. Diclofenac sodium had an antiexudative effect on the 7th day of its administration. Etoricoxib delayed the manifestation of symptoms of arthritis in animals, had an antiexudative effect on the 7th day of its administration, but increased the concentration of oxyproline in serum. EMHPS delayed the manifestation of symptoms of arthritis and reduced the concentration of oxyproline in serum. EMHPS when administered together with diclofenac sodium or etoricoxib had a corrective effect on the severity of symptoms of arthritis and reduced swelling on the 7th day of its administration. EMHPS when administered together with diclofenac sodium or etoricoxib but not NSAIDs and EMHPS per se reduced hyperalgesia on the 7th day of its administration. EMHPS when administered together with diclofenac sodium reduced the level of oxyproline, and when administered with etoricoxib, it prevented the increase in oxyproline level in the serum caused by etoricoxib. Conclusion . The combined use of EMHPS with diclofenac sodium and etoricoxib increases the effect of these NSAIDs in the collagen-induced arthritis model in BALB/c mice.
- 2 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (2)
Analgesic effect of N-phenylacetylglycyl-L-proline ethyl ester compared to cycloprolylglycine in formalin test in mice
Objective. To evaluate analgesic effect of N-phenylacetylglycyl-L-proline ethyl ester and cycloprolylglycine in formalin test in mice. Material and methods. Acute somatic pain in male ICR mice (n=48) was simulated by injecting 2.5% formalin into the hind paw. Throughout 30 min after injection, we recorded duration of pain reaction (paw raised above the floor of the chamber or tucked in; licking of the paw) in each phase: phase I (acute) (0-5 min); interphase (5-15 min); phase II (15-30 min). Analgesic effect of N-phenylacetylglycyl-L-proline ethyl ester and cycloprolylglycine was assessed after a single intraperitoneal injection 1 hour before testing at doses of 2 and 4 mg/kg. Results. N-phenylacetylglycyl-L-proline ethyl ester has the greatest analgesic effect at a dose of 2 mg/kg in interphase and phase II of formalin pain. Dose 4 mg/kg of dipeptide is effective only in interphase. Unlike its linear analogue, cycloprolylglycine 2 mg/kg reduces duration of pain reaction only in phase II. Conclusion. N-phenylacetylglycyl-L-proline ethyl ester at doses 2 and 4 mg/kg has analgesic effect in formalin test in mice. This effect is superior to cycloprolylglycine in efficacy, time of onset and duration.
- 2 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (2)
Analgesic effect of N-phenylacetylglycyl-L-proline ethyl ester compared to cycloprolylglycine in formalin test in mice
Objective. To evaluate analgesic effect of N-phenylacetylglycyl-L-proline ethyl ester and cycloprolylglycine in formalin test in mice. Material and methods. Acute somatic pain in male ICR mice (n=48) was simulated by injecting 2.5% formalin into the hind paw. Throughout 30 min after injection, we recorded duration of pain reaction (paw raised above the floor of the chamber or tucked in; licking of the paw) in each phase: phase I (acute) (0-5 min); interphase (5-15 min); phase II (15-30 min). Analgesic effect of N-phenylacetylglycyl-L-proline ethyl ester and cycloprolylglycine was assessed after a single intraperitoneal injection 1 hour before testing at doses of 2 and 4 mg/kg. Results. N-phenylacetylglycyl-L-proline ethyl ester has the greatest analgesic effect at a dose of 2 mg/kg in interphase and phase II of formalin pain. Dose 4 mg/kg of dipeptide is effective only in interphase. Unlike its linear analogue, cycloprolylglycine 2 mg/kg reduces duration of pain reaction only in phase II. Conclusion. N-phenylacetylglycyl-L-proline ethyl ester at doses 2 and 4 mg/kg has analgesic effect in formalin test in mice. This effect is superior to cycloprolylglycine in efficacy, time of onset and duration.
- 2 August 2024
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 177 (2) , 1-4
Protein Kinase A Inhibitor Attenuates the Antinociceptive Effect of NMDA-Receptor Channel Antagonists in the Capsaicin Test in Mice
Acute nociceptive pain in mice caused by subcutaneous (intraplantar) injection of TRPV1 ion channel agonist capsaicin (1.6 μg/mouse) and the effects o
- 2 August 2024
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 177 (2) , 1-4
Protein Kinase A Inhibitor Attenuates the Antinociceptive Effect of NMDA-Receptor Channel Antagonists in the Capsaicin Test in Mice
Acute nociceptive pain in mice caused by subcutaneous (intraplantar) injection of TRPV1 ion channel agonist capsaicin (1.6 μg/mouse) and the effects o
- 11 June 2024
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 87 (5) , 27-31
Влияние этилметилгидроксипиридина сукцината на вызванные ингибиторами циклооксигеназы повреждения слизистой оболочки желудка у крыс
На модели повреждения слизистой оболочки желудка у крыс, вызванного 3-дневным введением ацетилсалициловой кислоты (150 мг/кг, внутрь, через желудочный зонд), установлено, что диклофенак натрия (1 и 10 мг/кг) и эторикоксиб (1 и 10 мг/кг) дозозависимо усиливают выраженность повреждения слизистой оболочки. Так, диклофенак натрия значимо усугубляет влияние ацетилсалициловой кислоты при однократном (за 1 ч до третьего введения ацетилсалициловой кислоты) и троекратном (ежедневно за 1 ч до введения ацетилсалициловой кислоты) введении внутрь в дозе 10 мг/кг; эторикоксиб усиливает влияние ацетилсалициловой кислоты только при троекратном введении внутрь в дозе 10 мг/кг. Этилметилгидроксипиридина сукцинат при 1- и 3-кратном введении внутрь в дозе 25 мг/кг не оказывает значимого влияния на повреждения слизистой оболочки желудка, вызванные ацетилсалициловой кислотой. Однако этилметилгидроксипиридина сукцинат при совместном введении с диклофенаком натрия или эторикоксибом в дозе 10 мг/кг предупреждает появление значимого повреждающего действия ингибиторов циклооксигеназы на слизистую оболочку желудка.
- 11 June 2024
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 87 (5) , 27-31
Влияние этилметилгидроксипиридина сукцината на вызванные ингибиторами циклооксигеназы повреждения слизистой оболочки желудка у крыс
На модели повреждения слизистой оболочки желудка у крыс, вызванного 3-дневным введением ацетилсалициловой кислоты (150 мг/кг, внутрь, через желудочный зонд), установлено, что диклофенак натрия (1 и 10 мг/кг) и эторикоксиб (1 и 10 мг/кг) дозозависимо усиливают выраженность повреждения слизистой оболочки. Так, диклофенак натрия значимо усугубляет влияние ацетилсалициловой кислоты при однократном (за 1 ч до третьего введения ацетилсалициловой кислоты) и троекратном (ежедневно за 1 ч до введения ацетилсалициловой кислоты) введении внутрь в дозе 10 мг/кг; эторикоксиб усиливает влияние ацетилсалициловой кислоты только при троекратном введении внутрь в дозе 10 мг/кг. Этилметилгидроксипиридина сукцинат при 1- и 3-кратном введении внутрь в дозе 25 мг/кг не оказывает значимого влияния на повреждения слизистой оболочки желудка, вызванные ацетилсалициловой кислотой. Однако этилметилгидроксипиридина сукцинат при совместном введении с диклофенаком натрия или эторикоксибом в дозе 10 мг/кг предупреждает появление значимого повреждающего действия ингибиторов циклооксигеназы на слизистую оболочку желудка.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (3)
Ethylmethylhydroxypyridine succinate enhances analgesic effect of cyclooxygenase inhibitors in rats with postoperative hyperalgesia
Objective. To evaluate the effect of the antioxidant ethylmethylhydroxypyridine succinate (EMHPS) on the analgesic effects of cyclooxygenase (COX) inhibitors in a model of postoperative hyperalgesia in rats. Material and methods. Mechanical (von Frey test) hyperalgesia in the surgical suture area and metatarsus of rats was recorded for 4 days after surgery (longitudinal incisions of the skin and the flexor digitorum brevis muscle of the hind paw). A non-selective inhibitor of COX diclofenac sodium at a dose of 1 mg/kg and 10 mg/kg, followed by a dose reduction to 5 mg/kg due to the toxic effect of the drug, a selective inhibitor of COX-2 etoricoxib at a dose of 1 mg/kg and 10 mg/kg, EMHPS at a dose of 25 mg/kg administered orally twice a day, starting from the day of the surgery and for 3 days afterwards. Results. Etoricoxib at a dose of 10 mg/kg, but not at a dose of 1 mg/kg, reduced the postoperative hyperalgesia in the metatarsus on days 1, 2 and 3 after the surgery, and did not affect significantly the pain response in the surgical suture area. Diclofenac sodium and EMGPS did not have a significant effect on the sensitivity of animals to mechanical stimulation. However, EMGPS at a dose of 25 mg/kg together with diclofenac sodium at a dose of 1 mg/kg or etoricoxib at a dose of 1 mg/kg significantly reduced the sensitivity of rats with a model of postoperative pain on days 1, 2 and 3 after surgery. Conclusion. EMGPS at a dose of 25 mg/kg increases the analgesic effect of the non-selective COX inhibitor diclofenac sodium at a dose of 1 mg/kg and the selective COX-2 inhibitor etoricoxib at a dose of 1 mg/kg in mechanical hyperalgesia caused by surgical incisions in rats.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (3)
Ethylmethylhydroxypyridine succinate enhances analgesic effect of cyclooxygenase inhibitors in rats with postoperative hyperalgesia
Objective. To evaluate the effect of the antioxidant ethylmethylhydroxypyridine succinate (EMHPS) on the analgesic effects of cyclooxygenase (COX) inhibitors in a model of postoperative hyperalgesia in rats. Material and methods. Mechanical (von Frey test) hyperalgesia in the surgical suture area and metatarsus of rats was recorded for 4 days after surgery (longitudinal incisions of the skin and the flexor digitorum brevis muscle of the hind paw). A non-selective inhibitor of COX diclofenac sodium at a dose of 1 mg/kg and 10 mg/kg, followed by a dose reduction to 5 mg/kg due to the toxic effect of the drug, a selective inhibitor of COX-2 etoricoxib at a dose of 1 mg/kg and 10 mg/kg, EMHPS at a dose of 25 mg/kg administered orally twice a day, starting from the day of the surgery and for 3 days afterwards. Results. Etoricoxib at a dose of 10 mg/kg, but not at a dose of 1 mg/kg, reduced the postoperative hyperalgesia in the metatarsus on days 1, 2 and 3 after the surgery, and did not affect significantly the pain response in the surgical suture area. Diclofenac sodium and EMGPS did not have a significant effect on the sensitivity of animals to mechanical stimulation. However, EMGPS at a dose of 25 mg/kg together with diclofenac sodium at a dose of 1 mg/kg or etoricoxib at a dose of 1 mg/kg significantly reduced the sensitivity of rats with a model of postoperative pain on days 1, 2 and 3 after surgery. Conclusion. EMGPS at a dose of 25 mg/kg increases the analgesic effect of the non-selective COX inhibitor diclofenac sodium at a dose of 1 mg/kg and the selective COX-2 inhibitor etoricoxib at a dose of 1 mg/kg in mechanical hyperalgesia caused by surgical incisions in rats.
- 28 March 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (1)
Analgesic effect of externally applied and/or intraperitoneal hemantane and diclofenac in rats with postoperative pain
Objective. To evaluate the effect of hemantane administered by external application, intraperitoneal injection and combined external and intraperitoneal administration in rats with postoperative pain compared to diclofenac. Material and methods. Mechanical (von Frey test) or thermal (plantar test) hyperalgesia in rats was recorded for 4 days after surgery (longitudinal incisions of skin and flexor digitorum brevis muscle of the hind paw). Hemantane and diclofenac were applied to the paw and/or administered intraperitoneally twice a day on the day of surgery and 3 days after it. Results. Hemantane administered by external application (5% gel), intraperitoneal injection (10 mg/kg) and combined maneuver significantly reduced mechanical postoperative hyperalgesia. The effect of hemantane was superior the effect of diclofenac (5 mg/kg, 1% gel) when administered intraperitoneally or by combined approach. Effect of hemantane and diclofenac gels was similar. Both drugs had no significant effect on thermal postoperative hyperalgesia when administered via external or intraperitoneal route alone. Hemantane and diclofenac influenced thermal hyperalgesia only after topical application and simultaneous intraperitoneal injection. Conclusion. Low-affinity non-competitive NMDA receptor antagonist hemantane reduces mechanical hyperalgesia in rats with postoperative pain when applied topically (5% gel), intraperitoneally (10 mg/kg) or via both routes. Its effect is no inferior to diclofenac (5 mg/kg, 1% gel). Hemantane and diclofenac influenced thermal hyperalgesia only after topical application and simultaneous intraperitoneal injection.
- 28 March 2024
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 22 (1)
Analgesic effect of externally applied and/or intraperitoneal hemantane and diclofenac in rats with postoperative pain
Objective. To evaluate the effect of hemantane administered by external application, intraperitoneal injection and combined external and intraperitoneal administration in rats with postoperative pain compared to diclofenac. Material and methods. Mechanical (von Frey test) or thermal (plantar test) hyperalgesia in rats was recorded for 4 days after surgery (longitudinal incisions of skin and flexor digitorum brevis muscle of the hind paw). Hemantane and diclofenac were applied to the paw and/or administered intraperitoneally twice a day on the day of surgery and 3 days after it. Results. Hemantane administered by external application (5% gel), intraperitoneal injection (10 mg/kg) and combined maneuver significantly reduced mechanical postoperative hyperalgesia. The effect of hemantane was superior the effect of diclofenac (5 mg/kg, 1% gel) when administered intraperitoneally or by combined approach. Effect of hemantane and diclofenac gels was similar. Both drugs had no significant effect on thermal postoperative hyperalgesia when administered via external or intraperitoneal route alone. Hemantane and diclofenac influenced thermal hyperalgesia only after topical application and simultaneous intraperitoneal injection. Conclusion. Low-affinity non-competitive NMDA receptor antagonist hemantane reduces mechanical hyperalgesia in rats with postoperative pain when applied topically (5% gel), intraperitoneally (10 mg/kg) or via both routes. Its effect is no inferior to diclofenac (5 mg/kg, 1% gel). Hemantane and diclofenac influenced thermal hyperalgesia only after topical application and simultaneous intraperitoneal injection.
- 3 January 2024
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 86 (12) , 32-36
Влияние ингибиторов циклооксигеназы и их комбинаций с этилметилгидроксипиридина сукцинатом на уровень агрегируемых с поливинилпирролидоном липопротеинов низкой плотности в сыворотке крови крыс
В проведенном исследовании оценено влияние диклофенака натрия (1 и 5 мг/кг), эторикоксиба (1 и 10 мг/кг) и их комбинации в дозе 1 мг/кг с этилметилгидроксипиридина сукцинатом (ЭМГПС, 25 мг/кг) при курсовом пероральном введении (21 день) крысам на уровень агрегируемых с поливинилпирролидоном липопротеинов низкой плотности (апЛПНП) в сыворотке крови. Установлено, что эторикоксиб, но не диклофенак натрия, дозозависимо снижает уровень апЛПНП. ЭМГПС при курсовом пероральном введении не влияет на уровень апЛПНП в сыворотке крови крыс, но при совместном введении с эторикоксибом предупреждает его влияние на уровень апЛПНП.
- 3 January 2024
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 86 (12) , 32-36
Влияние ингибиторов циклооксигеназы и их комбинаций с этилметилгидроксипиридина сукцинатом на уровень агрегируемых с поливинилпирролидоном липопротеинов низкой плотности в сыворотке крови крыс
В проведенном исследовании оценено влияние диклофенака натрия (1 и 5 мг/кг), эторикоксиба (1 и 10 мг/кг) и их комбинации в дозе 1 мг/кг с этилметилгидроксипиридина сукцинатом (ЭМГПС, 25 мг/кг) при курсовом пероральном введении (21 день) крысам на уровень агрегируемых с поливинилпирролидоном липопротеинов низкой плотности (апЛПНП) в сыворотке крови. Установлено, что эторикоксиб, но не диклофенак натрия, дозозависимо снижает уровень апЛПНП. ЭМГПС при курсовом пероральном введении не влияет на уровень апЛПНП в сыворотке крови крыс, но при совместном введении с эторикоксибом предупреждает его влияние на уровень апЛПНП.